College of Clinical Medicine, Xi'an Medical University, Xi'an, 710021, China.
Xi'an Key Laboratory for Prevention and Treatment of Common Aging Diseases, Translational and Research Centre for Prevention and Therapy of Chronic Disease, Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, 710021, China.
Biomed Eng Online. 2024 Jul 13;23(1):67. doi: 10.1186/s12938-024-01263-7.
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with the worst prognosis. Radiotherapy (RT) is one of the core modalities for the disease; however, the ionizing radiation of RT has severe side effects. The consistent development direction of RT is to achieve better therapeutic effect with lower radiation dose. Studies have demonstrated that synergistic effects can be achieved by combining RT with non-ionizing radiation therapies such as light and magnetic therapy, thereby achieving the goal of dose reduction and efficacy enhancement.
In this study, we applied FeCo NPs with magneto thermal function and phototherapeutic agent IR-780 to construct an ionizing and non-ionizing radiation synergistic nanoparticle (INS NPs). INS NPs are first subjected to morphology, size, colloidal stability, loading capacity, and photothermal conversion tests. Subsequently, the cell inhibitory and cellular internalization were evaluated using cell lines in vitro. Following comprehensive assessment of the NPs' in vivo biocompatibility, tumor-bearing mouse model was established to evaluate their distribution, targeted delivery, and anti-tumor effects in vivo.
INS NPs have a saturation magnetization exceeding 72 emu/g, a hydrodynamic particle size of approximately 40 nm, a negatively charged surface, and good colloidal stability and encapsulation properties. INS NPs maintain the spectral characteristics of IR-780 at 808 nm. Under laser irradiation, the maximum temperature was 92 °C, INS NPs also achieved the effective heat temperature in vivo. Both in vivo and in vitro tests have proven that INS NPs have good biocompatibility. INS NPs remained effective for more than a week after one injection in vivo, and can also be guided and accumulated in tumors through permanent magnets. Later, the results exhibited that under low-dose RT and laser irradiation, the combined intervention group showed significant synergetic effects, and the ROS production rate was much higher than that of the RT and phototherapy-treated groups. In the mice model, 60% of the tumors were completely eradicated.
INS NPs effectively overcome many shortcomings of RT for TNBC and provide experimental basis for the development of novel clinical treatment methods for TNBC.
三阴性乳腺癌(TNBC)是一种预后最差的乳腺癌亚型。放射治疗(RT)是该疾病的核心治疗方法之一;然而,RT 的电离辐射具有严重的副作用。RT 的持续发展方向是以更低的辐射剂量实现更好的治疗效果。研究表明,RT 与光疗和磁疗等非电离辐射疗法相结合可以产生协同效应,从而实现降低剂量和提高疗效的目标。
在这项研究中,我们应用具有磁热功能和光热治疗剂 IR-780 的 FeCo NPs 构建了一种电离和非电离辐射协同纳米颗粒(INS NPs)。首先对 INS NPs 进行形态、粒径、胶体稳定性、载药量和光热转换测试。随后,通过体外细胞系评估细胞抑制和细胞内吞作用。在全面评估 NPs 的体内生物相容性后,建立荷瘤小鼠模型,评估其体内分布、靶向递送和抗肿瘤效果。
INS NPs 的饱和磁化强度超过 72 emu/g,水动力粒径约为 40nm,表面带负电荷,具有良好的胶体稳定性和包封性能。INS NPs 保持了 IR-780 在 808nm 处的光谱特性。在激光照射下,最大温度为 92°C,INS NPs 也实现了体内有效热温度。体内和体外试验均证明 INS NPs 具有良好的生物相容性。INS NPs 体内注射一次后,可维持一周以上的效果,同时还可以通过永磁体引导和聚集在肿瘤部位。随后的结果表明,在低剂量 RT 和激光照射下,联合干预组表现出显著的协同作用,ROS 产生率明显高于 RT 和光疗治疗组。在小鼠模型中,有 60%的肿瘤完全被根除。
INS NPs 有效克服了 RT 治疗 TNBC 的许多缺点,为开发 TNBC 新型临床治疗方法提供了实验基础。